Cc-chemokine eotaxin as a marker of efficacy of specific immunotherapy in patients with intermittent IgE-mediated allergic rhinoconjunctivitis.

Jahnz-Rózyk, K

Cc-chemokine eotaxin as a marker of efficacy of specific immunotherapy in patients with intermittent IgE-mediated allergic rhinoconjunctivitis. [electronic resource] - Allergy Jul 2003 - 595-601 p. digital

Publication Type: Comparative Study; Evaluation Study; Journal Article

0105-4538

10.1034/j.1398-9995.2003.00083.x doi


Administration, Inhalation
Adult
Allergens--adverse effects
Anti-Allergic Agents--therapeutic use
Betula--adverse effects
Biomarkers--blood
Chemokines, CC--blood
Conjunctivitis, Allergic--blood
Desensitization, Immunologic
Drug Therapy, Combination
Edible Grain--adverse effects
Female
Histamine H1 Antagonists, Non-Sedating--therapeutic use
Humans
Hypersensitivity, Immediate--blood
Immunoglobulin E--blood
Loratadine--therapeutic use
Male
Poaceae--adverse effects
Poland--epidemiology
Pollen--adverse effects
Rhinitis, Allergic, Seasonal--blood
Statistics as Topic
Treatment Outcome